Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation

Hiroaki Fujiiwa1,2, Keisuke Tateishi2*, Kento Misumi3, Akimasa Hayashi3, Kaori Igarashi4, Hiroyuki Kato1, Takuma Nakatsu1, Nobumi Suzuki2, Keisuke Yamamoto1, Yotaro Kudo1, Yoku Hayakawa5, Hayato Nakagawa1, Yasuo Tanaka1, Hideaki Ijichi1, Hirofumi Kogure1, Yosuke Nakai2, Hiroyuki Isayama6, Kiyoshi Hasegawa5, Masashi Fukayama3, Tomoyoshi Soga4 & Kazuhiko Koike1

Metabolism is a critical regulator of cell fate determination. Recently, the significance of metabolic reprogramming in environmental adaptation during tumorigenesis has attracted much attention in cancer research. Recurrent mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes have been identified in several cancers, including intrahepatic cholangiocarcinoma (ICC). Mutant IDHs convert α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), which affects the activity of multiple α-KG-dependent dioxygenases including histone lysine demethylases. Although mutant IDH can be detected even in the early stages of neoplasia, how IDH mutations function as oncogenic drivers remains unclear. In this study, we aimed to address the biological effects of IDH1 mutation using intrahepatic biliary organoids (IBOs). We demonstrated that mutant IDH1 increased the formation of IBOs as well as accelerated glucose metabolism. Gene expression analysis and ChIP results revealed the upregulation of platelet isoform of phosphofructokinase-1 (PFKP), which is a rate-limiting glycolytic enzyme, through the alteration of histone modification. Knockdown of the Pfkp gene alleviated the mutant IDH1-induced increase in IBO formation. Notably, the high expression of PFKP was observed more frequently in patients with IDH-mutant ICC compared to those with wild-type IDH (p < 0.01, 80.9% vs. 42.5%, respectively). Furthermore, IBOs expressing mutant IDH1 survived the suppression of ATP production caused by growth factor depletion and matrix detachment by retaining high ATP levels through 5′-adenosine monophosphate-activated protein kinase (AMPK) activation. Our findings provide a systematic understanding as to how mutant IDH induces tumorigenic preconditioning by metabolic rewiring in intrahepatic cholangiocytes.

Intrahepatic cholangiocarcinoma (ICC) is the second most common liver cancer with an overall poor prognosis1. Due to the limited effectiveness of drugs, the five-year survival rate remains less than 10%2. Primary risk factors of ICC include: infection by liver flukes or hepatitis virus, primary sclerosing cholangitis, and intrahepatic stones3. Although whole genomic sequencing has identified the mutational landscape of ICC4,5, its pathogenesis remains unclear.

The mutations in isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) genes are identified in 10–30% of ICC. Specifically, the mutations are found in ICC without the infection of liver flukes or hepatitis
Mutant IDH was reported to affect the initiation of Grade II/III gliomas or acute myeloid leukemia. Although ICC originates from several cell lineages including hepatocytes, cholangiocytes or, liver progenitor cells, how mutant IDH affects the molecular or biological features of normal intrahepatic cholangiocytes, we established IBOs from murine normal liver cells (Fig. 1A and Supplementary Fig. 1A)24. Given that organoids maintained the characteristics of primary cells24 we applied this system to estimate the biological and metabolic traits triggered by IDH1 mutation in normal biliary epithelial cells. IBOs were composed of a monolayer of biliary lineage cells expressing biliary marker genes, including cytokeratin 7 (CK7), cytokeratin 19 (CK19), and hepatocyte nuclear factor 4-alpha (HNF-4α)18,19, but not hepatocyte marker genes such as transthyretin (Ttr) and aldolase B (AldoB) (Fig. 1A and Supplementary Fig. 1A). Immunohistochemistry confirmed the expression of CK19 and SRY (sex determining region Y)-box 9 (SOX9) as biliary marker proteins in IBOs (Fig. 1B). The established IBOs were transduced with lentiviral vectors expressing human wild-type or mutant IDH1 (R132C) (Supplementary Fig. 1B). The activity of transduced mutated IDH1 was confirmed by production of 2-HG (Fig. 1C). We found that IBOs expressing mutant IDH1 (mut-IBOs) exhibited enhanced organoid-forming efficiency compared to IBOs expressing wild-type IDH1 (wt-IBOs), constitutively through serial passages (Fig. 1D, E). The 2-HG addition also enhanced the formation of IBOs after the third passage (Fig. 1F). In addition, a specific inhibitor of mutant IDH125, AGI-5198, significantly reduced the 2-HG production and hampered the formation of mut-IBOs. The effects were specific for mut-IBOs because AGI-5198 did not affect the growth of wt-IBOs (Fig. 1G,I). These results indicated that mutant IDH1 has the biological potential to enhance the IBO forming ability.

**Results**

**IDH1 mutation enhances the formation of biliary organoids established from murine liver.** To elucidate how mutant IDH affects the molecular or biological features of normal intrahepatic cholangiocytes, we established IBOs from murine normal liver cells (Fig. 1A and Supplementary Fig. 1A)24. Given that organoids maintained the characteristics of primary cells24 we applied this system to estimate the biological and metabolic traits triggered by IDH1 mutation in normal biliary epithelial cells. IBOs were composed of a monolayer of biliary lineage cells expressing biliary marker genes, including cytokeratin 7 (CK7), cytokeratin 19 (CK19), and hepatocyte nuclear factor 4-alpha (HNF-4α)18,19, but not hepatocyte marker genes such as transthyretin (Ttr) and aldolase B (AldoB) (Fig. 1A and Supplementary Fig. 1A). Immunohistochemistry confirmed the expression of CK19 and SRY (sex determining region Y)-box 9 (SOX9) as biliary marker proteins in IBOs (Fig. 1B). The established IBOs were transduced with lentiviral vectors expressing human wild-type or mutant IDH1 (R132C) (Supplementary Fig. 1B). The activity of transduced mutated IDH1 was confirmed by production of 2-HG (Fig. 1C). We found that IBOs expressing mutant IDH1 (mut-IBOs) exhibited enhanced organoid-forming efficiency compared to IBOs expressing wild-type IDH1 (wt-IBOs), constitutively through serial passages (Fig. 1D, E). The 2-HG addition also enhanced the formation of IBOs after the third passage (Fig. 1F). In addition, a specific inhibitor of mutant IDH125, AGI-5198, significantly reduced the 2-HG production and hampered the formation of mut-IBOs. The effects were specific for mut-IBOs because AGI-5198 did not affect the growth of wt-IBOs (Fig. 1G,I). These results indicated that mutant IDH1 has the biological potential to enhance the IBO forming ability.

**Mutant IDH1 upregulates glucose metabolism in IBOs.** To uncover metabolic traits underlying the increased forming ability in mut-IBOs, metabolic profiles of the IBOs were analyzed by capillary electrophoresis–mass spectrometry (CE–MS) (Fig. 2A and Supplementary Fig. 2). Notably, mut-IBOs displayed enrichment of glycolytic intermediates including fructose-1,6-bisphosphate (F1,6 P), 3-phosphoglycerate (3PG), 2-phosphoglycerate (2PG), phosphoenolpyruvate (PEP), and lactate compared with wt-IBO (Fig. 2A). In addition, the metabolites of other glucose-utilizing pathways sedoheptulose-7-phosphate (S7P), adenosine monophosphate (AMP), uridine monophosphate (UMP) in the pentose phosphate pathway (PPP), and UDP-N-acetylgalosamine in the hexosamine biosynthesis pathway (HBH), were significantly accumulated in mut-IBOs (Fig. 2A). Consistent with an increase in glycolysis, glucose uptake was significantly enhanced in mut-IBOs compared to wt-IBOs (Fig. 2B). Given that all of these metabolic profiles were identified under aerobic culture conditions with sufficient glucose and glutamine, such preferred aerobic glycolysis seemed to be similar to the ‘Warburg effect’ - a well-known hallmark of rapidly proliferating mammalian cells. However, some metabolites in the TCA cycle, including citrate, fumarate, and malate, were also elevated in mut-IBOs (Supplementary Fig. 2), indicating that mutations in IDH1 lead to higher glucose metabolism. Since reprogramming from differentiated cells to cancer cells is often accompanied by aerobic glycolytic phenotypes, we aimed to investigate if activated glycolysis correlates with the enhanced formation of mut-IBOs by treatment with a glycolytic inhibitor, 2-deoxy-d-glucose (2DG) (Fig. 3A). Although 2DG reduced the organoid-forming efficiency of both wt- and mut-IBOs in a dose-dependent manner, the formation of mut-IBOs was relatively resistant to the inhibitory effects of 2DG compared to wt-IBOs (Fig. 3B,C). The forming capacity of mut-IBOs compared to wt-IBOs was relatively conserved under a low glucose condition (Fig. 3D,E). These results suggest that the formation of IBOs depends on glucose as a critical energy source, and IDH1 mutation allows for IBOs to become resistant to glucose restriction.

**Mutant IDH1 activates glycolysis through the upregulation of Pfkp gene.** To address the molecular mechanisms underlying increased glycolysis in mut-IBO, we performed microarray gene expression analysis involving >40,000 oligonucleotide probes. Regardless of the drastic changes in organoid-forming efficiency and metabolism by IDH1 mutation, the analysis showed that only 19 genes were upregulated >2-fold, and 27 genes were downregulated <2-fold in mut-IBOs compared to wt-IBOs (P < 0.05, Supplementary Fig. 3A and Supplementary Table 1). Consistent with the effects of IDH1 mutation in terms of catalytic activities of αKG-dependent histone lysine demethylases, the levels of global histone H3 lysine 4 trimethylation (H3K4me3) and lysine 27 trimethylation (H3K27me3) were elevated in mut-IBOs, compared to wt-IBOs (Supplementary Fig. 3B) as previously reported in cancer cells. Expression of genes encoding enzymes such as Jari1a, Jari1b, or JmiD3 were not affected (Supplementary Fig. 3C). In contrast, there were no significant differences in the levels
Figure 1. *IDH1* mutation enhances the formation of biliary organoids established from murine liver. (A) The left panel shows a representative image of IBOs from wild-type mice (8-weeks old, male) at day 7. The middle and left panels show hematoxylin and eosin (HE) staining of them. Scale bars, 250 μm (middle and left panels) and 25 μm (right panel). (B) Immunohistochemical staining of Ck19 and Sox9 in IBOs. Scale bars, 20 μm. (C) The amount of 2-HG measured by CE-MS in cell extracts from IBOs stably expressing empty vector (EV), wild-type (Wild), and mutant IDH1 (R132C). (n = 4, *P < 0.05, NS not significant). (D) The number of IBOs (>100 μm) at 7 d after plating (n = 4, 3,000 cells per group, *P < 0.05) and their representative images. Scale bars, 250 μm. The assay was performed at passage 4. (E) Organoid-forming efficiency of the indicated IBOs during serial passage (P5–7) after puromycin selection. The number of organoids (>100 μm) at 7 d after plating (n = 4, 3,000 cells per group, *P < 0.05). (F) IBOs established from wild-type mice treated with 10 mM 2-HG (+) or vehicle (−) upon serial passage. The number of organoids (>100 μm) at 7 d after plating (n = 5, 3,000 cells per group, *P < 0.05, NS not significant). (G) 2-HG levels of mut-IBOs treated with 20 μM AGI-5198 (+) or DMSO vehicle (−). (H,I) The number (>100 μm) of mut-IBOs (H) and wt-IBOs (I) treated with 20 μM AGI-5198 (+) or DMSO vehicle at 7 d after plating (n = 4, 10,000 cells per group, *P < 0.05).
Figure 2. Mutant IDH1 increases glycolytic flux in IBOs. (A) Metabolome analysis of IBOs stably expressing empty vector (EV), wild-type IDH1 (Wild) or mutant IDH1 (R132C) by CE-MS (n = 4, *P < 0.05, NS not significant). (B) Glucose uptake in the indicated IBOs (n = 3, *P < 0.05). Abbreviation; α-KG, α-ketoglutarate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; CMP, cytidine monophosphate; CTP, cytidine triphosphate; DHAP, dihydroxyacetone phosphate; F1,6 P, fructose-1,6-bisphosphate; F6P, fructose 6-phosphate; GMP, guanosine monophosphate; G3P, glyceraldehyde 3-phosphate; G6P, glucose-6-phosphate; GTP, guanosine triphosphate; 6-PG, 6-phosphogluconate; PEP, phosphoenolpyruvate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosphate; S7P, sedoheptulose-7-phosphate; UDP, uridine diphosphate; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine; UMP, uridine monophosphate; UTP, uridine triphosphate.
of 5-hydroxymethylcytosine (5-hmC), 5-methylcytosine (5-mC), or in the expression of Tet family genes encoding DNA demethylase (Supplementary Fig. 3C–E). In addition, we analyzed the effects on chromatin structure caused by mutant IDH1 using an assay for transposase-accessible chromatin using sequencing (ATAC-seq)27. Although different peak patterns were detected in certain locations, there were no significant differences in specific motif sequences binding transcription factors (TFs) between wt- and mut-IBOs (Supplementary Fig. 4A–C). These results appear to be compatible with the lack of differences in DNA methylation, and the limited number of differentially expressed genes between wt- and mut-IBOs. Notably, however, we found a significant upregulation in the expression of the platelet isoform of phosphofructokinase-1 (Pfkp) gene in mut-IBOs (Fig. 4A). Mammalian phosphofructokinase-1 (PFK-1) is a tetramer consisting of three isoforms; Pfkl, Pfkm, and Pfkp28 and catalyzes the conversion of fructose 6-phosphate (F6P) to F1,6 P, which is a rate-limiting step in the glycolytic pathway. Intriguingly, the promotion of glycolysis in mut-IBOs occurred immediately downstream the transition of F6P to F1,6 P (Fig. 2A). This led us to hypothesize that IDH1 mutation drives glycolysis through the upregulation of Pfk-1 activity. Supporting our hypothesis, we confirmed not only increases in Pfkp mRNA and protein levels but also identified elevated Pfk-1 activity in mut-IBOs (Fig. 4A–D). To analyze if PFKP contributes to IBO formation, we established two distinct mut-IBO lines in which Pfkp was stably knocked-down (Fig. 4E). Both mut-IBO lines decreased the efficiency of IBO formation by mutant IDH1 (Fig. 4F), emphasizing the notion

Figure 3. The glycolytic inhibitor 2-DG or glucose restriction hampers the formation of IBOs, and mut-IBOs were resistant to the inhibition. (A) 2-DG competitively inhibits the conversion of G6P to F6P in glycolysis. (B) The number of organoids (>100μm) at 5 d after plating in medium with or without 2DG (normalized to that in the 2DG-free medium, n = 4, 5,000 cells per group *P < 0.05). (C) Representative images. Scale bars, 250μm. (D) The number of IBOs (>100μm) was counted at 7 d after plating under the normal culture condition (Normal) and the low glucose condition (Low glucose), replacing advanced-DMEM/F12 (3 g/L glucose) to L0091, glucose-free DMEM/F12 instead (n = 4, 5,000 cells per group, **P < 0.01). Low glucose medium contains a little glucose derived from Wnt3a- and RSPO1-conditioned medium; the final concentration of glucose is 0.2 g/L. (E) Representative images. Scale bars, 500μm.
that IDH1 mutation promotes IBO formation by enhancing glycolysis via upregulation of Pfkp. To examine the dysregulation of Pfkp directly caused by IDH1 mutation, the effect of the inhibitor AGI-5198 on the expression of the indicated IBOs. Time course of optical absorbance at 450 nm in (C), and comparison of PFK-1 activity in (D) (n = 4, *P < 0.05, **P < 0.01). (E) Gene expression of Pfkp in mut-IBOs transfected with shRNA for Pfkp (shPfkp-2, 5) or scrambled shRNA (Scr) as control (n = 4, *P < 0.05). (F) Organoid-forming efficiency of the indicated IBOs (>100 μm) at 7 days after plating (n = 4, 3000 cells per group, *P < 0.05). (G) Gene expression of Pfkp in mut-IBOs treated with 20 μM AGI-5198 (+) or DMSO vehicle (−) (n = 4, *P < 0.05). (H) IBOs established from wild-type mice were treated with 10 mM 2-HG (+) or vehicle (−) upon serial passage. Gene expression of Pfkp at passage 4 by RT-qPCR (n = 3, P = 0.14). (I) The level of trimethylation of histone H3 lysine4 (H3K4me3) on the promoter region of Pfkp by ChIP analysis in IBOs. The upper panel shows the schematic diagram of the transcriptional start site (TSS) and amplicons (0.2 kb and 50 kb downstream of the TSS). The lower graph shows ChIP-qPCR data (relative to input DNA, n = 4, *P < 0.05).

Figure 4. Mutant IDH1 activates glycolysis in IBOs through the upregulation of Pfkp. (A) The level of Pfkp expression in the indicated IBOs by RT-qPCR (n = 4, *P < 0.05, NS not significant). (B) Protein expression levels of Pfkp, Pfkm, and Pfkl as determined by western blotting. (C,D) Enzymatic assay of PFK-1 activity in the indicated IBOs. Time course of optical absorbance at 450 nm in (C), and comparison of PFK-1 activity in (D) (n = 4, *P < 0.05, **P < 0.01). (E) Gene expression of Pfkp in mut-IBOs transfected with shRNA for Pfkp (shPfkp-2, 5) or scrambled shRNA (Scr) as control (n = 4, *P < 0.05). (F) Organoid-forming efficiency of the indicated IBOs (>100 μm) at 7 days after plating (n = 4, 3000 cells per group, *P < 0.05). (G) Gene expression of Pfkp in mut-IBOs treated with 20 μM AGI-5198 (+) or DMSO vehicle (−) (n = 4, *P < 0.05). (H) IBOs established from wild-type mice were treated with 10 mM 2-HG (+) or vehicle (−) upon serial passage. Gene expression of Pfkp at passage 4 by RT-qPCR (n = 3, P = 0.14). (I) The level of trimethylation of histone H3 lysine4 (H3K4me3) on the promoter region of Pfkp by ChIP analysis in IBOs. The upper panel shows the schematic diagram of the transcriptional start site (TSS) and amplicons (0.2 kb and 50 kb downstream of the TSS). The lower graph shows ChIP-qPCR data (relative to input DNA, n = 4, *P < 0.05).
(Fig. 5B). Considering the significance of PFKP for growth advantage in many human cancers\textsuperscript{29,30}, PFKP could serve as a novel metabolic target for IDH1-mutant ICCs.

**IDH1 mutation provides EGF- and HGF-independent survival in IBOs.** We sought to assess the biological consequences of mutant IDH1-induced glycolytic activation. Consistent with previous reports showing that mutant IDH1 alone is insufficient for transformation in several cell linages\textsuperscript{16,20}, subcutaneous inoculation of either wt-IBO or mut-IBO into nude mice failed to generate tumors (2,000,000 cells per group, n = 6, data not shown). The organoid culture systems are applied to the assessment of extracellular factor-dependency\textsuperscript{31}. Based on the findings that cultured organoids gradually become independent of growth factors followed by oncogenic mutations\textsuperscript{31}, we evaluated the effect of *IDH1* mutation for growth factor-dependency in the survival of IBOs. Depletion of EGF, FGF10, HGF, or R-spondin-1 significantly reduced the organoid-forming efficiency of wt-IBO (Supplementary Fig. 5A,B). Although the efficiency of mut-IBO formation decreased in the absence of EGF, FGF10, HGF, or R-spondin-1, the higher organoid-forming efficiency compared to wt-IBO was still observed.
Mutant IDH1-induced AMPK activation makes IBOs override the EGF and HGF dependency.

To address the molecular mechanisms underlying the sustained survival after EH-depletion, we examined the status of signal transduction pathways related to cell survival (Fig. 7A and Supplementary Fig. 6). The levels of phosphorylation of Erk, Akt, or Stat3 were comparable between wt-IBOs and mut-IBOs (Fig. 7A). In addition, these phosphorylation levels were not affected by EH-depletion (Fig. 7A). In contrast, we identified enhanced phosphorylation of AMP-activated protein kinase (AMPK) in mut-IBOs compared to wt-IBOs, regardless of EH-depletion (Fig. 7A). The two primary upstream regulators of AMPK, Lkb1, and Camkk2 were not differently activated between mut-IBOs and wt-IBOs (Supplementary Fig. 7). Intriguingly, among the multiple downstream targets of the AMPK signaling pathway53, Unc-51 like kinase-1 (Ulk1), which is a crucial initiator of autophagy54, was activated by EH-depletion only in mut-IBOs (Fig. 7A and Supplementary Fig. 7). To address whether AMPK activation contributed to the sustained formation of IBOs under EH-depletion, mut-IBOs were treated with the AMPK inhibitor, Compound C54. The organoid-forming capacity after EH-depletion in mut-IBOs was entirely inhibited by Compound C (Fig. 7B,C), suggesting that AMPK contributes to the growth-factor independence in cooperation with IDH1 mutation. Given that 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), which is a well-known AMP analog that activates AMPK, inhibited the formation of wt-IBOs (Supplementary Fig. 8), Thus, the role of AMPK seems to be context-dependent, as previously reported55.

It is well-known that growth factor deprivation, as well as detachment from the extracellular matrix (ECM), induces ATP loss and subsequent cell death in normal epithelial cells56. When organoids are passaged as dissociated single cells, they must be exposed to energy stress without growth factors or ECM. Supporting this notion, wt-IBOs were not formed in the settings without matrigel after passage procedures. Thus, we compared the levels of cellular ATP in dissociated IBO cells just after the passage procedure (Fig. 7D,E). Mounting of the dissociated wt-IBO cells on matrigel with complete medium after passage recovered ATP production in a time-dependent manner, but EH-depletion from medium inhibited the recovery (Fig. 7E). In contrast, the dissociated mut-IBO cells restored the high levels of ATP after passage, even under EH-depletion (Fig. 7E). Given the function of AMPK in replenishing ATP after the loss of ECM attachment56, we considered that AMPK activation contributed to ATP production in dissociated mut-IBO cells. Consistently, AMPK inhibition significantly decreased ATP levels in the dissociated mut-IBO cells (Fig. 7F). These data supported the notion that AMPK activity contributes to ATP production under EH-depletion in mut-IBOs.

Discussion

In this study, we found a unique metabolic status in the IDH- mutant biliary cells. Several previous reports have described the phenotype of IDH-mutant cancer cells related to hypoxia-inducible factor 1 (HIF-1α) activity. For example, the survival and proliferation of IDH-mutant glioma cells were promoted by the Warburg effect due to the stabilization of HIF-1α57,58. In contrast, other studies have shown that IDH mutations downregulate the HIF-1α pathway and induce limited glycolysis, contributing to the slower growth and better prognosis in glioma cells59. Although we do not entirely exclude the possible involvement of HIF-1α in the IDH- mutant biliary cells, the expression of Hif-1α protein and the majority of its downstream glycolytic genes were not markedly upregulated in mut-IBOs (Supplementary Fig. 9). Upregulated HIF-1α expression by IDH1 mutation reduced the energy flux through the TCA cycle and increased the clonogenicity of normal human astrocytes due to the activation of pyruvate dehydrogenase kinases (PDKs)59. In contrast, levels of some metabolites in the TCA cycle, including citrate, fumarate, and malate were elevated in mut-IBOs (Supplementary Fig. 2). Additionally, decreased levels of glutamate identified in glioma or astrocytes harboring IDH1 mutation40 were not observed in the case of mut-IBOs (Supplementary Fig. 2). These findings propose a possibility that metabolic rewiring traits triggered by IDH mutation are different among distinct cell lineages. Furthermore, while mutant IDH in patient material...
of glioma and glioblastoma was associated with a non-Warburg phenotype in comparison with wild-type IDH tumors, the artificial introduction of mutant IDH into glioblastoma cell lines resulted in aerobic glycolysis. Thus, the metabolic effects of mutant IDH can also vary between patient-derived materials and those established experimentally. To assess the possibility of clinical trials focusing on the metabolic traits of mutant IDH tumors as in gliomas, the metabolome analysis of clinical samples of ICC would be needed in the near future.

It was noteworthy that there was a difference in the organoid-forming efficiency between mut-IBOs and wt-IBOs treated with 2-HG (Fig. 1D–F). We speculate two possibilities for the different extent of growth promotion. The first is a possibility that the intracellular concentration of 2-HG in wt-IBO cells treated with 2-HG was lower than in mut-IBOs due to the limited cell permeability of R-2-HG or the run-in effect. The second is a possible 2-HG independent function of mutant IDH1, which might be supported by a previous paper showing that DNA methylation profiles of 2-HG treated cells could not entirely recapitulate those of mutant IDH1 cells. In general, as the increasing level of AMP mirrors the decrease in ATP under metabolic stress conditions in normal cells, the metabolic situation caused by IDH1 mutation seems to be extraordinary, where both AMP and ATP accumulated. Similarly, the activation of AMPK in mut-IBOs was rather paradoxical in terms of its energy sensor function because ATP levels remained unperturbed in mut-IBOs (Fig. 2). As the AMP-induced activation of AMPK is allosterically much more potent than the inhibitory action of ATP based on structural research, AMPK activation in mut-IBOs was likely to be induced by AMP accumulation (Fig. 2).

Despite the tumor-suppressive roles of AMPK in many cancers, recent studies have shown the pleiotropic properties of AMPK for tumor cell survival under metabolic stress. In terms of the relationships of AMPK and...
IDH mutation, previous reports demonstrated the metabolic vulnerability of mutant IDH gliomas or glioblastomas to biguanides, such as metformin and phenformin, which activate AMPK by inhibiting mitochondrial respiratory chain complex. Therefore, our findings emphasize the notion that the role of AMPK seems to be pleiotropic and context-dependent.

Finally, we identified a two-way metabolic rewiring status: PFKP upregulation and AMPK activation induced by IDH1 mutation in normal biliary cells (Fig. 8). Nonetheless, it is still necessary to elucidate the whole mechanism acquired by IDH1 mutation that finally accomplishes biliary tumor development.

**Methods**

**Liver organoid culture.** Organoids derived from murine liver were established according to published protocols. Resected mouse liver was minced under sterile conditions, washed in Hank's balanced salt solution without Ca²⁺ and Mg²⁺ (HBSS−) containing 10 mM HEPES, 0.5 mM EDTA, and then naturally sedimented. After removal of the supernatant, the minced liver was digested in HBSS+ containing 10 mM HEPES, 1 mg/mL of collagenase type 4 (Invitrogen, Carlsbad, CA) and 0.5 mg/mL of pronase (Sigma-Aldrich, St. Louis, MO, USA) for 10–15 min. The suspension was filtered through cell strainers (100 μm) and sedimented by centrifugation (700 × g) for 3 min. After hemolytic treatment, the pellet was mixed with Matrigel (BD Bioscience, San Jose, CA) and cultured as previously described. Culture medium was based on Advanced DMEM/F12 (Invitrogen) supplemented with B27 (Invitrogen), N2 (InvivoGen, San Diego, CA), 1.25 μM N-acetylcysteine (Wako, Osaka, Japan), 50 ng/mL EGF (Wako), 100 ng/mL FGF10 (Wako), 50 ng/mL HGF (R&D Systems, Minneapolis, MN), 10% RSPO1-conditioned medium (kindly gifted from C. Kuo and prepared as previously reported), 10 nM gastrin (Sigma-Aldrich), and 10 mM nicotinamide (Sigma-Aldrich). For the first 4 d after seeding, the cells were also supplemented with 100 ng/mL Noggin (PeproTech, Rocky Hill, NJ) and 10% Wnt3a-conditioned medium (prepared as previously reported). Next, 1 week after seeding, organoids were mechanically dissociated and transferred to fresh gels.

**Construction of IDH1 mutation and lentiviral infection.** Human wild-type IDH1 expression vector (plasmid pFN21AE0433) was purchased from Kazusa DNA Research Institute (Chiba, Japan). The IDH1 R132C mutant was generated from the wild-type IDH1 open reading frame of this plasmid using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Rosa, CA) and primers 5'-GATCCCCA TAAGGATGACACACGCTATGATGATAGGTTC-3' for sense and 5'-GAACCTATCATCATAGGTTG TCATGCTTATGGGGATC-3' for antisense. The wild-type and mutant IDH1 were ligated into the multiple cloning sites of pLVSIN-EF1α Vector (TAKARA, Shiga, Japan) and these lentiviral vectors were transfected into 293 T/17 cells. Organoids were infected with concentrated lentivirus supernatant for 9–12 h and selected with puromycin (2 μg/mL).

Transduction was validated by reverse transcriptase-polymerase chain reaction (RT-PCR) using specific primers for mutant IDH1 (R132C): 5'-GGGTAACCATCTCATCATAGGTTT-3', 5'-TCCAGGCCCCAGGAA CAACAA-3', and wild-type IDH1: 5'-GGGTAACCATCTCATCATAGGTTT-3', 5'-TCCAGGCCCCAGGAA CAACAA-3'.

**shRNA.** Lentiviral (pLKO.1) Pfkp shRNA vectors TRCN0000025916 and TRCN0000025962 were purchased from Dharmaco Inc. (Lafayette, CO). and used as shPfkp-2 and shPfkp-5, respectively. The puromycin-resistance gene was excised with restriction enzymes, and the hygromycin-resistance gene was ligated into the same region of each vector.
Capillary electrophoresis-mass spectrometry (CE-MS). Organoids were collected through complete
dilution of gels by Cell Recovery Solution (BD Bioscience, San Jose, CA, USA) and washed twice with 5% m anni-
tol in order to extract the metabolites. Methanol containing 25 μM each of methionine sulfone, 2-(N-morpholino)
ethanesulfonic acid (MES), and (-)-Camphor-10-sulfonic acid was added to cell pellets, which were left to rest
for 10 min at room temperature. Samples in solution were mixed with water and chloroform, centrifuged at
10,000 × g for 3 min at 4 °C, and the aqueous phase of the solution was removed. The extract was transferred to a
5 kDa ultrafiltration tube (Human Metabolome Technologies, Yamagata, Japan) and centrifuged at 9,100 × g for
2 h at 20 °C. CE-MS was used to analyze the filtrate in Dr. Soga’s laboratory, as previously described50.

Transcriptional analysis. GENE CHIP Expression Analysis microarrays were performed following the
manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). Total RNA was extracted from murine liver organ-
oids expressing human wild type IDH1 and mutant IDH1 (R132C), at passage three after transfection.

Animals. All experiments were performed under protocols approved by the Animal Ethics Committee of The
University of Tokyo. The research was conducted with guidelines approved by the Office of Laboratory Animal
Welfare (Ref: F18-000412). C57BL/6 mice were purchased from CLEA (Shizuoka, Japan).

Products. AGI-5198 was purchased from Cayman Chemical (Ann Arbor, MI). R(-)-2-hydroxygluturate
(2-HG) and 2-deoxy-d-glucose (2DG) were purchased from Sigma-Aldrich. Cell Titer-Glo was purchased from
Promega (Madison, WI). Compound C (ab146597) was purchased from Abcam (Cambridge, UK). DMEM/F12
without Glucose (L0091) was purchased from Biowest (Nuaille, France).

Clinical samples, molecular analysis, and PFKP scoring system. Formalin-fixed, paraffin-embedded
(FFPET) tissue blocks from 101 patients with ICC who underwent surgical treatment at the University of Tokyo
Hospital were used for the extraction of tumor DNA. Mutational analysis of IDH was performed by direct
sequencing of PCR products. FFPE tissue sections were immunohistochemically stained using the primary anti-
body against PFKP (ab119796, Abcam). Staining results were scored by two pathologists (K.M. and A.H.) blinded
to the mutational profile of IDH. The scoring system was validated by the percentages of positive cells as follows:
score 0, <1%; score 1, 1–5%; score 2, 6–25%; score 3, 26–50%; and score 4, >51%. Simultaneously, scores 0
and 1 were defined as negative expression, score 2 as low, score 3 as moderate, and score 4 was defined as high
expression, respectively. Detailed procedures for immunohistochemistry and DNA sequencing were previously
described51. This study was approved by the Ethics Committee of the University of Tokyo, and carried out in
accordance with the Declaration of Helsinki. Informed consent in writing was obtained from all patients.

PFK-1 activity assay. 6-Phosphofructokinase Activity Assay Kit (ab155898, Abcam) was used in accordance with
the manufacturer’s protocol. Briefly, for each assay, 900,000 cells were harvested and washed in cold PBS.
After suspension and appropriate dilution in the assay buffer, cellular extracts were mixed with the reaction
solution containing ATP and F6P. NADH produced by the reaction was monitored spectrophotometrically at 450 nm
for 100 min. PFK-1 activity was calculated from an NADH standard curve.

Glucose uptake assay. Glucose Uptake Assay Kit (ab136955, Abcam) was used in accordance with
the manufacturer’s protocol. Briefly, organoids were treated in Krebs-Ringer-Phosphate-Hepes (KRPH) buffer:
20 mM HEPES, 5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl, and 4.7 mM KCl, at a pH 7.4 con-
taining 2% bovine serum albumin (BSA), with or without 2-DG (1 mM), for 20 min. Organoids were harvested
and washed in cold PBS. For each assay, we used 70,000 cells. Harvested cells were lysed with extraction buffer,
frozen at −80 °C for 15 min, and heated at 85 °C for 40 min. After cooling on ice for 5 min, the lysates were neu-
tralized by adding neutralization buffer and diluted approximately with assay buffer. Lastly, by two amplification
steps, according to the manufacturer’s instructions, the colorimetric end product was detected at 412 nm. From
the 2-DG-6-phosphate (2-DG6P) standard curve, 2-DG (or glucose) uptake was calculated.

Quantitative real-time reverse transcriptase-PCR (RT-qPCR). RT-qPCR was performed as previously
described52. RNA was extracted from organoids using RNeasy Mini Kit (Qiagen, Hilden, Germany).
Values were internally normalized against β-actin (Actb) mRNA expression. PCR primer sequences are listed in
Supplementary Table 2.

Immunohistochemistry. Organoids were fixed in 4% paraformaldehyde (PFA) in PBS. The slides were
hematoxylin & eosin (H&E) stained and subjected to histological analysis. Immunohistochemistry was per-
formed as previously described52. The primary antibodies used were anti-Ck19 (DSHB, AB-2133570, 1:100) and
anti-Sox9 (Sigma-Aldrich, AB5535, 1:1000).

Immunoblotting. Harvested organoids were lysed in RIPA buffer (10 mM Tris–HC1 [pH 7.4], 150 mM
NaCl, 2 mM EDTA, 1% NP40, 0.1% Na deoxycholate, 0.1% SDS, 50 mM NaF, 1 mM Na3VO4, and a protease
inhibitor cocktail (Complete Mini, Roche, Basel, Switzerland), then sonicated for 5 min. After centrifugation
at 15,000 × g for 15 min, supernatants were collected as whole cell lysates. Immunoblotting was performed as
previously described82. The primary antibodies used were anti-β-actin (Sigma-Aldrich, A5441, 1:10,000),
anti-Akt (Cell Signaling, 9272, 1:1,000), anti-phosphorylated-Akt (Cell Signaling, 9271, 1:1,000), anti-Histone
H3 (Abcam, ab1791, 1:1,000), anti-H3K9me3 (Abcam, ab8898, 1:1,000), anti-H3K4me1 (Abcam, ab9045, 1:1,000),
anti-H3K4me3 (Abcam, ab8580, 1:1,000), anti-H3K27me3 (Abcam, ab6002, 1:1,000), anti-Pfkp
(Abcam, ab119796, 1:500), anti-Pdk1 (Abcam, ab37583, 1:500), anti-Pfk (Proteintech, 55028-1-AP, 1:800),
anti-Erk (Cell Signaling, 9102, 1:1000), anti- phosphorylated Erk (Cell Signaling, 9101, 1:1000), anti-Ampk (Cell
Dot blot analysis. Genomic DNA samples were collected from organoids using QIAamp DNA Mini Kit (Qiagen). Dot blot analysis was performed as described previously. The primary antibodies used were anti-5-hydroxymethylcytosine (5-hmC) (39769, 1:10,000, Active Motif, Carlsbad, CA, USA) and anti-5-Methylcytosine (5-mC) (NA81, 1:1,000, Merck Millipore, Burlington, MA, USA).

ATAC-seq. ATAC-seq experiments were performed on 100,000 cells from the organoid samples, following published protocols. We prepared the samples from wt-/mut-IBOs, at passage 8. Processing of ATAC-Seq reads were performed as follows. Sequence reads were trimmed and aligned to the mouse genome (mm10) using BWA. PCR duplicates were removed using Picard's MarkDuplicates, and peaks were called using MACS2. Called peaks were further processed to obtain scatter-plots, correlation heat maps, and Venn diagrams using DiffBind.

Chromatin immunoprecipitation (ChIP). ChIP was performed as previously described. We prepared 1.5 × 10^6 cells from liver organoids expressing human wild type IDH1 and mutant IDH1 for each assay. Antibodies used for ChIP were H3K4me3 (ab8580, Abcam) and normal Rabbit IgG (CST2729, Cell Signaling Technology, Danvers, MA). ChIP primers are listed in Supplementary Table 3.

Statistical analysis. Data are presented as means ± standard error of the mean (SEM). Statistical significance was evaluated by the two-tailed Student’s t-test. * denotes P < 0.05, and **P < 0.01. To test the correlation between PFKP expression and IDH status in human ICC samples, Fisher’s exact test was used.

Data availability. The datasets analyzed in the current study are available from the corresponding author on reasonable request. Microarray gene expression data are in Gene Expression Omnibus (GSE134760).

Published: xx xx xxxx; Received: 14 September 2019; Accepted: 22 November 2019;

References
1. Rizvi, S. & Gores, G. J. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. *Gastroenterology* **145**, 1215–1229 (2013).
2. Everhart, J. E. & Ruhl, C. E. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. *Gastroenterology* **136**, 1134–44 (2009).
3. Tyson, G. L. & El Serag, H. B. Risk factors for cholangiocarcinoma. *Hepatology* **54**, 173–184 (2011).
4. Zou, S. et al. Methylomic landscape of intrahepatic cholangiocarcinoma. *Nature Communications* **5**, 5696 (2014).
5. Fujimoto, A. et al. Whole-genome methylomic landscape and characterization of noncoding and structural mutations in liver cancer. *Nat Genet* **48**, 500–509 (2016).
6. Borger, D. R. et al. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. *The Oncologist* **17**, 72–79 (2012).
7. Chan-on, W. et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nat Genet* **45**, 1474–1478 (2013).
8. Lowery, M. A. et al. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. *Clin Cancer Res* **24**, 4154–4161 (2018).
9. Nepal, C. et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. *Hepatology* **68**, 949–963 (2018).
10. Parshudhar, F. et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Rep* **19**, 2878–2880 (2017).
11. Cairns, R. A. & Mak, T. W. Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities. *Cancer Discovery* **3**, 730–741 (2013).
12. Dang, L. et al. Cancer–associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* **462**, 739–744 (2009).
13. Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO reports* **12**, 463–469 (2011).
14. Xu, W. et al. Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases. *Cancer cell* **19**, 17–30 (2011).
15. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* **483**, 474–478 (2012).
16. Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. *Nature* **488**, 656–659 (2012).
17. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* **483**, 479–483 (2012).
18. Fan, B. et al. Cholangiocarcinomas can originate from hepatocytes in mice. *The Journal of Clinical Investigation* **122**, 2911–2915 (2012).
19. Guest, R. V. et al. Cell Lineage Tracing Reveals a Biliary Origin of Intrahepatic Cholangiocarcinoma. *Cancer Research* **74**, 1005–1010 (2014).
20. Saha, S. K. et al. Mutant IDH inhibits HNF-4(α) to block hepatocyte differentiation and promote biliary cancer. *Nature* **513**, 110–114 (2014).
21. Sato, T. et al. Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche. *Nature* **459**, 262–265 (2009).
Acknowledgements
We thank Mitsuko Tsubouchi and Sayaka Ito for providing assistance with various cell cultures; and all of the lab members for their helpful comments. This project was supported by Grants-in-Aid for Scientific Research (18K07899) and for Early-Career Scientists (19K17391) from the Japan Society for the Promotion of Science.

Author contributions
H.F. and K.T. conceived study designs. H.F. performed most of the experiments and wrote the manuscript. K.M., A.H., and M.F. validated the profiles of IDH status and P.F.K.P. expression of human I.C.C. samples provided by K.H. K.I. and T.S. performed metabolic analysis. H.K. analyzed ATAC-seq data. T.N., N.S., K.Y., Y.H., H.N., Y.T., H.I. (Hideaki Ijichi), H.K., Y.N. and H.I. (Hiroyuki Isayama) provided technical and material supports. K.K. and K.H. K.I. and T.S. performed metabolic analysis. H.K. analyzed ATAC-seq data. T.N., N.S., K.Y., Y.H., H.N., A.H., and M.F. validated the profiles of IDH status and P.F.K.P. expression of human I.C.C. samples provided by K.H. K.I. and T.S. performed metabolic analysis. H.K. analyzed ATAC-seq data. T.N., N.S., K.Y., Y.H., H.N., Y.T., H.I. (Hideaki Ijichi), H.K., Y.N. and H.I. (Hiroyuki Isayama) provided technical and material supports. K.K. supervised the study. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.
